On January 11, BioMarin Pharmaceutical announced that Jeffrey Ajer would step down as the company’s Executive Vice President and Chief Commercial Officer, effective July 1, the company disclosed in a regulatory filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMRN:
- William Blair biotech analysts to hold an analyst/industry conference call
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- BioMarin price target raised to $93 from $80 at Bernstein
- BioMarin announces governance enhancements, value creation initiatives
- BioMarin CLO Davis sells 13,764 common shares